Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
Clinical trial NCT05350917 · UNKNOWN
Trial details
- NCT number
- NCT05350917
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-20
- Primary completion
- 2025-06-20
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.